This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2022 Jun;63(6):855-859.

doi: 10.2967/jnumed.121.262989. Epub 2021 Sep 16.

¹⁸F-DCFPyL PET Acquisition, Interpretation, and Reporting: Suggestions After Food and Drug Administration Approval

Hong Song¹, Andrei Iagaru², Steven P Rowe³

Affiliations

Affiliations

¹ Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California; and.
² Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California; and aiagaru@stanford.edu.
³ Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland.

PMID: 34531266
DOI: 10.2967/jnumed.121.262989

Free article

¹⁸F-DCFPyL PET Acquisition, Interpretation, and Reporting: Suggestions After Food and Drug Administration Approval

Hong Song et al. J Nucl Med. 2022 Jun.

Free article

. 2022 Jun;63(6):855-859.

doi: 10.2967/jnumed.121.262989. Epub 2021 Sep 16.

Authors

Hong Song¹, Andrei Iagaru², Steven P Rowe³

Affiliations

¹ Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California; and.
² Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California; and aiagaru@stanford.edu.
³ Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland.

PMID: 34531266
DOI: 10.2967/jnumed.121.262989

No abstract available

PubMed Disclaimer

Similar articles

¹⁸F-DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes: Detection Rate, Image Quality, Activity Kinetics, and Biodistribution.
Wondergem M, van der Zant FM, Knol RJJ, Lazarenko SV, Pruim J, de Jong IJ. Wondergem M, et al. J Nucl Med. 2017 Nov;58(11):1797-1804. doi: 10.2967/jnumed.117.192658. Epub 2017 Apr 27. J Nucl Med. 2017. PMID: 28450569
Combined model-based and patient-specific dosimetry for ¹⁸F-DCFPyL, a PSMA-targeted PET agent.
Plyku D, Mena E, Rowe SP, Lodge MA, Szabo Z, Cho SY, Pomper MG, Sgouros G, Hobbs RF. Plyku D, et al. Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):989-998. doi: 10.1007/s00259-018-3939-x. Epub 2018 Feb 19. Eur J Nucl Med Mol Imaging. 2018. PMID: 29460025 Free PMC article.
Regulatory Agencies and PET/CT Imaging in the Clinic.
Herscovitch P. Herscovitch P. Curr Cardiol Rep. 2022 Oct;24(10):1361-1371. doi: 10.1007/s11886-022-01749-7. Epub 2022 Aug 1. Curr Cardiol Rep. 2022. PMID: 35913674 Free PMC article. Review.
Comparison of 18F-DCFPyL and 18F-FDG PET/computed tomography for the restaging of clear cell renal cell carcinoma: preliminary results of 15 patients.
Liu Y, Wang G, Yu H, Wu Y, Lin M, Gao J, Xu B. Liu Y, et al. Nucl Med Commun. 2020 Dec;41(12):1299-1305. doi: 10.1097/MNM.0000000000001285. Nucl Med Commun. 2020. PMID: 32941403
Clinical and Technical Considerations for Brain PET Imaging for Dementia.
Acuff SN, Mathotaarachchi S, Zukotynski K, Osborne D, Subramaniam R; Alzheimer’s Disease Neuroimaging Initiative. Acuff SN, et al. J Nucl Med Technol. 2020 Mar;48(1):5-8. doi: 10.2967/jnmt.118.220087. Epub 2019 Jun 10. J Nucl Med Technol. 2020. PMID: 31182663 Review.

See all similar articles

Cited by

Radiolabeled PSMA Inhibitors.
Neels OC, Kopka K, Liolios C, Afshar-Oromieh A. Neels OC, et al. Cancers (Basel). 2021 Dec 13;13(24):6255. doi: 10.3390/cancers13246255. Cancers (Basel). 2021. PMID: 34944875 Free PMC article. Review.
Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer.
Chen J, Qi L, Tang Y, Tang G, Gan Y, Cai Y. Chen J, et al. Front Cell Dev Biol. 2022 Aug 12;10:958180. doi: 10.3389/fcell.2022.958180. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36036001 Free PMC article. Review.
The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer.
Kase AM, Tan W, Copland JA 3rd, Cai H, Parent EE, Madan RA. Kase AM, et al. Cancers (Basel). 2022 Mar 8;14(6):1361. doi: 10.3390/cancers14061361. Cancers (Basel). 2022. PMID: 35326513 Free PMC article. Review.
Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.
Harsini S, Martineau P, Plaha S, Saprunoff H, Chen C, Bishop J, Tyldesley S, Wilson D, Bénard F. Harsini S, et al. Cancer Imaging. 2024 Aug 30;24(1):117. doi: 10.1186/s40644-024-00752-1. Cancer Imaging. 2024. PMID: 39210431 Free PMC article.
Can ¹⁸F-PSMA-7Q PET/CT replace prostate biopsy for the diagnosis of prostate cancer?-A single-center retrospective study.
Liu Y, Niu S, Luan X, Zhang X, Liu J, Zhang J, Wang R, Xu B, Zhang X. Liu Y, et al. Transl Androl Urol. 2023 Jan 30;12(1):83-89. doi: 10.21037/tau-22-813. Epub 2023 Jan 12. Transl Androl Urol. 2023. PMID: 36760865 Free PMC article.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire